CYSLTR1 and prostate carcinoma: Montelukast also inhibited hypoxia-induced HIF-1α activation in prostate cancer cells, but the effect was not shown by pranlukast and zafirlukast, suggesting this effect was not mediated by the CysLT1R pathway [69].